Get started
Author

Emanuela Romagnoli

Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents
2017 · Matteo Santoni, Emanuela Romagnoli, et al. · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 245
Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications
2019 · Matteo Santoni, Giulia Occhipinti, et al. · BioDrugs · 52
Gastric cancer treatment: a systematic review
2004 · Rossana Berardi, Mario Scartozzi, et al. · Oncology Reports · 26
Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER+HER2−Rb wild-type and knock-down in breast cancer cell lines
2020 · Oliviero Marinelli, Emanuela Romagnoli, et al. · BMC Cancer · 11
PDF
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications
2020 · Giulia Occhipinti, Emanuela Romagnoli, et al. · Frontiers in Genetics · 11
PDF
Effective prevention of 5-fluorouracil–induced superficial phlebitis by ketoprofen lysine salt gel
2003 · Rossana Berardi, Andrea Piga, et al. · The American Journal of Medicine · 10
PDF
Compliance with Breast and Cervical Cancer Screening Programs in Women: Results from a Population-Based Study
2013 · Rossana Berardi, Dania Nacciarriti, et al. · Tumori Journal · 8
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study
2022 · Nicla La Verde, Giovanna Damia, et al. · Breast Cancer Research · 6
PDF
Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells
2024 · Matteo Giulietti, Francesco Piva, et al. · Cells · 5
PDF
Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial
2022 · Roberta Caputo, Alessandra Fabi, et al. · Breast Cancer Targets and Therapy · 4
PDF
Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
2026 · Giampaolo Bianchini, Luca Malorni, et al. · Clinical Cancer Research · 3
PDF
Correlation between NDRG1 gene polymorphism and neuropathy (N) in metastatic breast cancer (MBC) patients (pts) enrolled in the PAINTER study (Polymorphism And INcidence of Toxicity in ERibulin treatment).
2019 · Nicla Maria La Verde, Giovanna Damia, et al. · Journal of Clinical Oncology · 3
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study
2023 · Marina Elena Cazzaniga, Paolo Pronzato, et al. · Cancers · 2
PDF
Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study.
2019 · Giorgio Mustacchi, Paolo Pronzato, et al. · Journal of Clinical Oncology · 2
Validation of time to treatment change (TTC) as a surrogate end-point of progression free survival (PFS) for observational trials in metastatic breast cancer patients (MBC): The GIM-13 AMBRA study.
2018 · Marina Elena Cazzaniga, Paolo Pronzato, et al. · Journal of Clinical Oncology · 2
Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13 - AMBRA Study
2017 · M. Cazzaniga, G. Mustacchi, et al. · Annals of Oncology · 2
PDF
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
2019 · Marina Elena Cazzaniga, Claudio Verusio, et al. · Breast Care · 1
PDF
Choice of treatment and adherence to international ESO-ESMO (ABC) guidelines in HR+/HER2-ve metastatic breast cancer (MBC) patients (pts).
2017 · Marina Elena Cazzaniga, Giorgio Mustacchi, et al. · Journal of Clinical Oncology · 1
The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.
2017 · Giorgio Mustacchi, Marina Elena Cazzaniga, et al. · Journal of Clinical Oncology · 1
Supplementary Methods S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
2026 · Giampaolo Bianchini, Luca Malorni, et al.
Supplementary Figure S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
2026 · Giampaolo Bianchini, Luca Malorni, et al.
Supplementary Figure S3 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
2026 · Giampaolo Bianchini, Luca Malorni, et al.
Supplementary Figure S2 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
2026 · Giampaolo Bianchini, Luca Malorni, et al.
Supplementary Data S1 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
2026 · Giampaolo Bianchini, Luca Malorni, et al.
Supplementary Table S3 from Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
2026 · Giampaolo Bianchini, Luca Malorni, et al.
Works count: 51
Citation count: 395
H-index: 7
I10-index: 6
Year
Topic
Type